RB1 and cancer: Given that cancer cells often hyperactivate ribosome production (24), our study underscores the potential of harnessing conserved microRNAs for chemotherapy as standalone therapeutics or in concert with other potent small molecule inhibitors of RB like BMH-21 to simultaneously target pre-rRNA transcription and processing.